Phase I Trial With "Off-The-Shelf" Third-Party BPX-501 Donor Lymphocyte Immunotherapy to Treat Persistence or Relapse of Hematologic Malignancies After Allogeneic Stem Cell Transplantation

This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant. Donor T-cell therapy (rivogenlecleucel) may help control transplant-related infections after stem cell transplant.

开始日期2020-01-02

申办/合作机构

Fred Hutchinson Cancer Research Center

[+2]

NCT03699475

/ Terminated临床2/3期

A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS

This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.

开始日期2018-12-27

申办/合作机构

Bellicum Pharmaceuticals, Inc.

NCT03459170

/ Active, not recruiting临床1期

A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant

Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.

开始日期2018-02-01

申办/合作机构

Bellicum Pharmaceuticals, Inc.

100 项与 Rivogenlecleucel 相关的临床结果

登录后查看更多信息

100 项与 Rivogenlecleucel 相关的转化医学

登录后查看更多信息

100 项与 Rivogenlecleucel 相关的专利（医药）

登录后查看更多信息

项与 Rivogenlecleucel 相关的文献（医药）

2018-05-01·Bone marrow transplantation3区 · 医学

BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia

3区 · 医学

Letter

作者: Ho, Christine ; Amro Elshoury ; Kader, Angela ; Hahn, Theresa ; Borowitz, Michael J ; Ross, Maureen ; Wallace, Paul K ; Chen, George L ; O'Neill, Vince ; Choi, Chris ; McCarthy, Philip L ; Balderman, Sophia

This study presents an unusual complication of BPX-501 T cells affecting the clin. work flow and emphasizing the need for good communication between providers and the laboratoryThe patient is a 24-yr-old female with Philadelphia chromosome pos. precursor B-cell acute lymphoblastic leukemia (pre-B-ALL) in first complete remission who received an αβ T-cell depleted, CD34+ selected haploidentical peripheral blood hematopoietic stem cell transplant (HSCT) after myeloablative conditioning with fludarabine, cyclophosphamide, anti-thymocyte globulin, rituximab, and total body irradiation

项与 Rivogenlecleucel 相关的新闻（医药）

2023-01-30

·PRNewswire

Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companies Working in the Domain

The incidence of AML has gradually increased around the globe. Males and older people had a higher possibility to develop AML. Developed countries tended to have higher age-standardized incidence rates and death rates than developing regions. Novel therapies for AML, including refinements of conventional cytotoxic chemotherapies, genetic and epigenetic targeted drugs, as well as immunotherapies, have significantly improved patient outcomes in recent years. LAS VEGAS, Jan. 30, 2023 /PRNewswire/ -- DelveInsight's ' Acute Myeloid Leukemia Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline acute myeloid leukemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the acute myeloid leukemia pipeline domain. Key Takeaways from the Acute Myeloid Leukemia Pipeline Report DelveInsight's acute myeloid leukemia pipeline report depicts a robust space with 200+ active players working to develop 260+ pipeline therapies for acute myeloid leukemia treatment. Key acute myeloid leukemia companies such as GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others are evaluating new acute myeloid leukemia drugs to improve the treatment landscape. Promising acute myeloid leukemia pipeline therapies in various stages of development include Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others. In January 2023, Innate Pharma SA announced the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. In January 2023, the FDA granted JBI-802 orphan drug designation for patients diagnosed with small cell lung cancer (SCLC) and acute myeloid leukemia (AML), according to a press release from Jubilant Therapeutics. In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) had granted orphan-drug designation (ODD) to the oral fixed-dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML). Request a sample and discover the recent advances in acute myeloid leukemia drug treatment @ Acute Myeloid Leukemia Pipeline Report The acute myeloid leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage acute myeloid leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the acute myeloid leukemia clinical trial landscape. Acute Myeloid Leukemia Overview Acute myeloid leukemia (AML) is the most common type of leukemia in adults, accounting for roughly 80% of all cases. Clonal expansion of immature "blast cells" in the peripheral blood and bone marrow results in ineffective erythropoiesis and bone marrow failure. There are various types of AML. Each affects a different type of blood cell. The acute myeloid leukemia symptoms you experience are determined by the type of blood cell that is affected. The common acute myeloid leukemia symptoms include tiredness, weakness, pale skin, irregular heartbeat, dizziness, and others. Many tests are used for acute myeloid leukemia diagnosis. Doctors will also perform tests to determine the subtype of AML. Chemotherapy is the primary treatment for most AML types, sometimes in conjunction with a targeted therapy drug. A stem cell transplant could follow this. Other drugs (aside from standard chemotherapy drugs) may be used to treat people with acute promyelocytic leukemia (APL). Find out more about drugs for acute myeloid leukemia @ New Acute Myeloid Leukemia Drugs A snapshot of the Acute Myeloid Leukemia Pipeline Drugs mentioned in the report: Learn more about the emerging acute myeloid leukemia pipeline therapies @ Acute Myeloid Leukemia Clinical Trials Acute Myeloid Leukemia Therapeutics Assessment The acute myeloid leukemia pipeline report proffers an integral view of acute myeloid leukemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Acute Myeloid Leukemia Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous Therapeutics Assessment By Molecule Type: Small molecule, Cell therapy, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Cell replacements, E-selectin inhibitors, Interleukin-15 receptor agonists, Immunologic cytotoxicity, T lymphocyte replacements, Bcr-abl tyrosine kinase inhibitors, Epidermal growth factor receptor antagonists, Fms-like tyrosine kinase 3 inhibitors, Lyn protein-tyrosine kinase inhibitors, NEDD 8 activating enzyme inhibitors Key Acute Myeloid Leukemia Companies: GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others. Key Acute Myeloid Leukemia Pipeline Therapies: Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others. Dive deep into rich insights for new drugs for acute myeloid leukemia treatment; visit @ Acute Myeloid Leukemia Medications Table of Contents For further information on the acute myeloid leukemia pipeline therapeutics, reach out @ Acute Myeloid Leukemia Drug Treatment Related Reports Acute Myeloid Leukemia Market Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted relapsed/refractory acute myeloid leukemia epidemiology in the 7MM. Acute Lymphocytic Leukemia Pipeline Acute Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others. Chronic Lymphocytic Leukemia Pipeline Chronic Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lymphocytic leukemia companies, including Celgene, Loxo Oncology, Octapharma, among others. Chronic Myeloid Leukemia Pipeline Chronic Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic myeloid leukemia companies, including Kartos Therapeutics, Novartis, Incyte Corporation, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Upcoming Oncology Drugs Oncology Market Outlook Future of Oncology Market Related Cases Studies Competitive Intelligence Market Assessment Product Assessment Epidemiology Assessment Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

免疫疗法孤儿药ASCO会议

2017-12-08

·BioPortfolio

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases

ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced results from a leading European transplant center participating in the BP-004 trial in children with blood cancers and nonmalignant disorders. Patients were treated with BPX-501 following an alpha/beta T cell and CD19+ B cell depleted haploidentical hematopoietic stem cell transplant (haplo-HSCT). Results demonstrated that donor BPX-501 cells infused after transplant expanded in vivo and persisted over time, contributing to improved immune recovery for patients in the study as compared to historical controls from the same transplant center. The data were reviewed in an oral presentation today during the 59th Annual Meeting of the American Society of Hematology (ASH). According to study author and presenter Pietro Merli of Ospedale Pediatrico Bambino Gesù in Rome, “These data show that administering BPX-501 cells following a haplo-HSCT may result in improved immune recovery and infection control, addressing significant risks in children undergoing a stem cell transplant who do not have access to a matched donor. Adding BPX-501 to a haplo-HSCT has the potential to improve outcomes and to make the curative benefits of transplants available to more children with cancers and genetic blood diseases.” Study Design and Highlights (Abstract #211) Investigators evaluated immune recovery and outcomes of 112 pediatric patients who underwent a haplo-HSCT followed by treatment with BPX-501. Children in the study had acute leukemia (n=53), Primary Immune Deficiencies (n=26), erythroid disorders (n=17), Fanconi anemia (n=7), and other diseases (n=9). All patients were transplanted after depletion of donor alpha/beta T cells and CD19 B cells to prevent graft-versus-host disease (GvHD) and post-transplant lymphoproliferative disorders (PTLD). BPX-501 cells were scheduled to be infused approximately two weeks post-transplant. Results showed: BPX-501 cells infused after haplo-HSCT expand and persist in patients, potentially contributing to improved recovery of adaptive immunity. Peak expansion of BPX-501 cells is reached at nine months after infusion, and BPX-501 cells are consistently detected after two years. CMV infection is a main driver of BPX-501 cell expansion, suggesting that BPX-501 cells cooperate in clearing the viral infection. The overall pattern of immune recovery in 112 children studied may be improved when compared to patients who received a similar haplo-HSCT without BPX-501. “Improved immune recovery and control over infections, as demonstrated in this study, may have a direct impact on treatment-related morbidity and mortality,” commented Rick Fair, Bellicum’s President & Chief Executive Officer. “We look forward to reporting on these and other outcomes from our ongoing BP-004 trial in 2018.” A copy of the ASH presentation will be made available in the “Investors & Media” section of the Company’s website. About BPX-501 BPX-501 is an adjunct T cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD occur. This enables physicians to more safely perform stem cell transplants by administering BPX-501 engineered T cells to speed immune reconstitution, provide control over viral infections and enhance Graft-versus-leukemic effect without unacceptable GvHD risk. The ongoing BP-004 clinical study of BPX-501 is being conducted at transplant centers in the U.S. and Europe. About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com. Forward-Looking Statement This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to BPX-501, BPX-601, BPX-701, rimiducid, CaspaCIDe, iMC, dual switch, CAR-T and TCR programs; the effectiveness of BPX-501, BPX-601 and BPX-701, their possible ranges of application and potential curative effects and safety in the treatment of diseases, including as compared to other treatment options and competitive therapies; the timing and success of our clinical trials, including our BP-004 study and observational trials; the rate and progress of enrollment in our clinical trials for BPX-501, BPX-601 and BPX-701, including our planned registration trials for BPX-501 and rimiducid; the timing of regulatory filings for BPX-501 and rimiducid; our research and development activities relating to our GoCAR-T and GoTCR technologies, and our collaborations with academic institutions. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2016 and our report on Form 10-Q for the quarter ended March 31, 2017. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Investors: Bellicum Pharmaceuticals, Inc. Alan Musso, CFO 832-384-1116 amusso@bellicum.com Media: BMC Communications Brad Miles 917-570-7340 bmiles@bmccommunications.com or BMC Communications Amy Bonanno 914-450-0349 abonanno@bmccommunications.com Source: Bellicum Pharmaceuticals NEXT ARTICLE More From BioPortfolio on "Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases" Related Companies Related Clinical Trials Related PubMed Entries Related Medications

小分子药物合作细胞疗法免疫疗法

100 项与 Rivogenlecleucel 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11145	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床3期	美国	Bellicum Pharmaceuticals, Inc.	2018-12-27
骨髓增生异常综合征	临床3期	美国	Bellicum Pharmaceuticals, Inc.	2018-12-27
急性淋巴细胞白血病	临床3期	-	Bellicum Pharmaceuticals, Inc.	-
再生障碍性贫血	临床2期	美国	Bellicum Pharmaceuticals, Inc.	2014-04-01
先天性单纯性红细胞再生障碍性贫血	临床2期	意大利	Bellicum Pharmaceuticals, Inc.	2014-04-01
先天性单纯性红细胞再生障碍性贫血	临床2期	英国	Bellicum Pharmaceuticals, Inc.	2014-04-01
镰状细胞血症	临床2期	意大利	Bellicum Pharmaceuticals, Inc.	2014-04-01
镰状细胞血症	临床2期	英国	Bellicum Pharmaceuticals, Inc.	2014-04-01
范可尼贫血	临床2期	意大利	Bellicum Pharmaceuticals, Inc.	2014-04-01
范可尼贫血	临床2期	英国	Bellicum Pharmaceuticals, Inc.	2014-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02231710 (CTgov)	临床1期	噬血细胞性淋巴组织细胞增多症 \| 原发性免疫缺陷疾病 \| 代谢性疾病 ... 更多	1	Rimiducid+BPX-501	膚鹹構膚網窪糧觸構繭(鏇觸壓繭鏇鏇鹽簾獵鬱) = 鏇選糧願鏇顧網淵遞選鏇築顧鏇窪鹽獵構廠繭 (壓艱鬱築構範顧糧餘簾, 顧鹽齋選齋衊憲壓糧夢 ~ 鏇廠鑰觸築遞齋衊糧鏇) 更多	-	2024-03-25
NCT03699475 (THRIVE, CTgov)	临床2/3期	急性髓性白血病 \| 骨髓增生异常综合征	1	rimiducid+rivogenlecleucel	淵願築選壓積遞遞鏇繭(膚觸鑰築醖鏇鹹襯窪顧) = 憲壓鬱餘鏇築築鏇構簾膚艱鹽蓋顧鑰願餘願蓋 (夢網獵網鹽積衊窪醖壓, 醖糧鏇齋簾鹹積膚餘醖 ~ 製艱夢憲顧蓋醖壓廠構) 更多	-	2023-09-01
NCT02065869 (O103 \| BP-004 \| P404, CTgov)	临床1/2期	先天性单纯性红细胞再生障碍性贫血 \| 急性淋巴细胞白血病 \| 大理石病 ... 更多	187	Rimiducid+BPX-501 T cells	遞鏇網繭襯鹽鹹衊廠憲(廠鑰積鑰襯鬱築醖糧衊) = 鏇襯艱膚範糧積鏇觸醖襯淵艱鹽鹹襯蓋齋蓋製 (鬱鹹獵觸窪壓鹽廠顧糧, 蓋糧鏇餘襯積齋鹽積蓋 ~ 夢鏇選齋鏇願網窪廠願)	-	2023-01-04
NCT02065869 (BP-004, Corporate Publications) 人工标引	临床2期	造血干细胞移植	-	Rivogenlecleucel+rimiducid	築鬱製窪繭鏇鏇積憲製(鑰構積觸製壓鑰夢範壓) = 範醖顧蓋齋範衊艱積壓選衊鹹齋遞築鹹醖鑰窪 (淵鏇壓鹹構齋壓簾餘積, 84.8 ~ 94.6)	积极	2019-07-08
NCT02065869 (P404, EBMT2019)	临床1/2期	造血干细胞移植	142	BPX-501 (CMV-reactivating group)	廠衊顧襯壓襯鹹製簾遞(鹹範餘糧膚鏇蓋願積鹹) = 觸觸糧淵鏇製鬱廠網築膚憲襯淵餘窪艱蓋築築 (網襯繭遞觸窪遞構蓋鹹 ) 更多	积极	2019-03-24
NCT02065869 (P404, EBMT2019)	临床1/2期	造血干细胞移植	142	BPX-501 (CMV-non reactivating group)	廠衊顧襯壓襯鹹製簾遞(鹹範餘糧膚鏇蓋願積鹹) = 淵艱夢選製糧遞鏇範憲膚憲襯淵餘窪艱蓋築築 (網襯繭遞觸窪遞構蓋鹹 ) 更多	积极	2019-03-24
Tandem Meetings ASTCT and CIBMTR2019	N/A	急性白血病	100	BPX-501	簾糧醖淵衊壓憲觸網壓(淵網蓋廠鏇蓋構夢範蓋) = 餘選獵築鬱築製蓋繭淵襯鹽艱膚廠夢願範選窪 (製鑰願窪鑰餘網選膚壓 ) 更多	积极	2019-03-01
Tandem Meetings ASTCT and CIBMTR2019	N/A	急性白血病	100	Rimiducid	繭餘廠選獵壓鹹願選餘(襯淵淵醖襯願觸糧鹹糧) = 淵淵壓衊顧構憲蓋淵衊醖簾艱壓構鹹範範醖膚 (鏇繭繭選鏇糧鹹廠鹹觸 )	积极	2019-03-01
FOCIS2018	N/A	原发性免疫缺陷疾病	59	BPX-501 (Alpha/Beta T-cell and B-cell Depleted HLA-haploidentical HSCT)	鏇製構壓夢憲選範壓襯(構廠艱衊選憲廠夢範齋) = 夢鹹壓鏇積願憲網簾觸餘壓積糧鬱簾襯衊觸衊 (廠壓糧廠艱選憲鹹淵壓 ) 更多	积极	2018-06-20
EHA2017	临床1/2期	血液肿瘤	104	BPX-501 (αβ T-cell depleted Haplo-HSCT)	鹽衊選糧獵選鑰願鏇窪(觸範鹹顧壓蓋艱鏇積遞) = 願膚醖築夢壓遞遞網簾範鹹網襯鑰網範艱鏇鏇 (獵製簾夢製廠築簾鬱積 ) 更多	-	2017-05-18